PDBsum entry 1ycr

Go to PDB code: 
protein Protein-protein interface(s) links
Complex (oncogene protein/peptide) PDB id
Protein chains
85 a.a. *
13 a.a. *
* Residue conservation analysis
PDB id:
Name: Complex (oncogene protein/peptide)
Title: Mdm2 bound to the transactivation domain of p53
Structure: Mdm2. Chain: a. Fragment: residues 17 - 125. Synonym: mdm2. Engineered: yes. P53. Chain: b. Fragment: residues 15 - 29. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562.
Biol. unit: Dimer (from PQS)
2.60Å     R-factor:   0.200     R-free:   0.276
Authors: P.H.Kussie,N.P.Pavletich
Key ref: P.H.Kussie et al. (1996). Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274, 948-953. PubMed id: 8875929
30-Sep-96     Release date:   19-Nov-97    
Go to PROCHECK summary

Protein chain
Pfam   ArchSchema ?
Q00987  (MDM2_HUMAN) -  E3 ubiquitin-protein ligase Mdm2
491 a.a.
85 a.a.
Protein chain
Pfam   ArchSchema ?
P04637  (P53_HUMAN) -  Cellular tumor antigen p53
393 a.a.
13 a.a.
Key:    PfamA domain  Secondary structure  CATH domain

 Gene Ontology (GO) functional annotation 
  GO annot!
  Biological process     protein ubiquitination   2 terms 


Science 274:948-953 (1996)
PubMed id: 8875929  
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
P.H.Kussie, S.Gorina, V.Marechal, B.Elenbaas, J.Moreau, A.J.Levine, N.P.Pavletich.
The MDM2 oncoprotein is a cellular inhibitor of the p53 tumor suppressor in that it can bind the transactivation domain of p53 and downregulate its ability to activate transcription. In certain cancers, MDM2 amplification is a common event and contributes to the inactivation of p53. The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix. The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft. These same p53 residues are also involved in transactivation, supporting the hypothesis that MDM2 inactivates p53 by concealing its transactivation domain. The structure also suggests that the amphipathic alpha helix may be a common structural motif in the binding of a diverse family of transactivation factors to the TATA-binding protein-associated factors.

Literature references that cite this PDB file's key reference

  PubMed id Reference
23303139 M.Wade, Y.C.Li, and G.M.Wahl (2012).
MDM2, MDMX and p53 in oncogenesis and cancer therapy.
  Nat Rev Cancer, 13, 83-96.  
21152588 A.R.Bizzarri, and S.Cannistraro (2011).
Free energy evaluation of the p53-Mdm2 complex from unbinding work measured by dynamic force spectroscopy.
  Phys Chem Chem Phys, 13, 2738-2743.  
21244642 C.Riedinger, M.E.Noble, D.J.Wright, F.Mulks, I.R.Hardcastle, J.A.Endicott, and J.M.McDonnell (2011).
Understanding small-molecule binding to MDM2: insights into structural effects of isoindolinone inhibitors from NMR spectroscopy.
  Chem Biol Drug Des, 77, 301-308.  
20882600 D.A.Guarracino, B.N.Bullock, and P.S.Arora (2011).
Protein-protein interactions in transcription: A fertile ground for helix mimetics.
  Biopolymers, 95, 1-7.  
20690138 D.J.van de Wijngaart, H.J.Dubbink, M.Molier, Vos, G.Jenster, and J.Trapman (2011).
Inhibition of androgen receptor functions by gelsolin FxxFF peptide delivered by transfection, cell-penetrating peptides, and lentiviral infection.
  Prostate, 71, 241-253.  
21378965 E.Vojnic, A.Mourão, M.Seizl, B.Simon, L.Wenzeck, L.Larivière, S.Baumli, K.Baumgart, M.Meisterernst, M.Sattler, and P.Cramer (2011).
Structure and VP16 binding of the Mediator Med25 activator interaction domain.
  Nat Struct Mol Biol, 18, 404-409.
PDB code: 2xnf
21335238 G.B.Deutsch, E.M.Zielonka, D.Coutandin, T.A.Weber, B.Schäfer, J.Hannewald, L.M.Luh, F.G.Durst, M.Ibrahim, J.Hoffmann, F.H.Niesen, A.Sentürk, H.Kunkel, B.Brutschy, E.Schleiff, S.Knapp, A.Acker-Palmer, M.Grez, F.McKeon, and V.Dötsch (2011).
DNA damage in oocytes induces a switch of the quality control factor TAp63α from dimer to tetramer.
  Cell, 144, 566-576.  
21261729 J.Wang, T.Zheng, X.Chen, X.Song, X.Meng, N.Bhatta, S.Pan, H.Jiang, and L.Liu (2011).
MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
  J Gastroenterol Hepatol, 26, 371-377.  
21057528 K.M.Draheim, N.Hermance, Y.Yang, E.Arous, J.Calvo, and M.A.Kelliher (2011).
A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice.
  Oncogene, 30, 1252-1260.  
21172813 S.Teotia, and R.S.Lamb (2011).
RCD1 and SRO1 are necessary to maintain meristematic fate in Arabidopsis thaliana.
  J Exp Bot, 62, 1271-1284.  
21425280 T.Terakawa, T.Kameda, and S.Takada (2011).
On easy implementation of a variant of the replica exchange with solute tempering in GROMACS.
  J Comput Chem, 32, 1228-1234.  
21170087 X.Xiong, Y.Zhao, H.He, and Y.Sun (2011).
Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator.
  Oncogene, 30, 1798-1811.  
  20833732 Y.Li, X.Dai, Y.Cheng, and Y.Zhao (2011).
NPY genes play an essential role in root gravitropic responses in Arabidopsis.
  Mol Plant, 4, 171-179.  
  20516128 A.C.Joerger, and A.R.Fersht (2010).
The tumor suppressor p53: from structures to drug discovery.
  Cold Spring Harb Perspect Biol, 2, a000919.  
19557013 A.G.Eldridge, and T.O'Brien (2010).
Therapeutic strategies within the ubiquitin proteasome system.
  Cell Death Differ, 17, 4.  
20588277 A.K.Arya, A.El-Fert, T.Devling, R.M.Eccles, M.A.Aslam, C.P.Rubbi, N.Vlatković, J.Fenwick, B.H.Lloyd, D.R.Sibson, T.M.Jones, and M.T.Boyd (2010).
Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53.
  Br J Cancer, 103, 186-195.  
20235143 A.Mazars, and R.Fåhraeus (2010).
Using BRET to study chemical compound-induced disruptions of the p53-HDM2 interactions in live cells.
  Biotechnol J, 5, 377-384.  
20480050 A.Patil, K.Kinoshita, and H.Nakamura (2010).
Hub promiscuity in protein-protein interaction networks.
  Int J Mol Sci, 11, 1930-1943.  
21152297 B.Xue, A.K.Dunker, and V.N.Uversky (2010).
Retro-MoRFs: Identifying Protein Binding Sites by Normal and Reverse Alignment and Intrinsic Disorder Prediction.
  Int J Mol Sci, 11, 3725-3747.  
20100603 B.Xue, R.L.Dunbrack, R.W.Williams, A.K.Dunker, and V.N.Uversky (2010).
PONDR-FIT: a meta-predictor of intrinsically disordered amino acids.
  Biochim Biophys Acta, 1804, 996.  
19923193 C.J.Brown, A.K.Johnson, and G.W.Daughdrill (2010).
Comparing models of evolution for ordered and disordered proteins.
  Mol Biol Evol, 27, 609-621.  
20226197 C.Li, M.Pazgier, C.Li, W.Yuan, M.Liu, G.Wei, W.Y.Lu, and W.Lu (2010).
Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
  J Mol Biol, 398, 200-213.
PDB code: 3lnz
20669189 C.M.Yang, and J.Zhang (2010).
Insights into intramolecular Trp and His side-chain orientation and stereospecific π interactions surrounding metal centers: an investigation using protein metal-site mimicry in solution.
  Chemistry, 16, 10854-10865.  
21168768 C.R.Braun, J.Mintseris, E.Gavathiotis, G.H.Bird, S.P.Gygi, and L.D.Walensky (2010).
Photoreactive stapled BH3 peptides to dissect the BCL-2 family interactome.
  Chem Biol, 17, 1325-1333.  
20711647 C.S.Busso, M.W.Lake, and T.Izumi (2010).
Posttranslational modification of mammalian AP endonuclease (APE1).
  Cell Mol Life Sci, 67, 3609-3620.  
20962272 C.W.Lee, J.C.Ferreon, A.C.Ferreon, M.Arai, and P.E.Wright (2010).
Graded enhancement of p53 binding to CREB-binding protein (CBP) by multisite phosphorylation.
  Proc Natl Acad Sci U S A, 107, 19290-19295.  
20662736 D.D.Dudgeon, S.N.Shinde, T.Y.Shun, J.S.Lazo, C.J.Strock, K.A.Giuliano, D.L.Taylor, P.A.Johnston, and P.A.Johnston (2010).
Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.
  Assay Drug Dev Technol, 8, 437-458.  
20308326 E.Herbig, L.Warfield, L.Fish, J.Fishburn, B.A.Knutson, B.Moorefield, D.Pacheco, and S.Hahn (2010).
Mechanism of Mediator recruitment by tandem Gcn4 activation domains and three Gal11 activator-binding domains.
  Mol Cell Biol, 30, 2376-2390.  
19755569 E.Hunt, S.Gattolin, H.J.Newbury, J.S.Bale, H.M.Tseng, D.A.Barrett, and J.Pritchard (2010).
A mutation in amino acid permease AAP6 reduces the amino acid content of the Arabidopsis sieve elements but leaves aphid herbivores unaffected.
  J Exp Bot, 61, 55-64.  
19931997 F.Bai, F.Zhu, M.Tagen, L.Miller, T.S.Owens, J.Mallari, E.Derrick, F.Zhang, and C.F.Stewart (2010).
Determination of nutlin-3a in murine plasma by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).
  J Pharm Biomed Anal, 51, 915-920.  
21075307 F.Bernal, M.Wade, M.Godes, T.N.Davis, D.G.Whitehead, A.L.Kung, G.M.Wahl, and L.D.Walensky (2010).
A stapled p53 helix overcomes HDMX-mediated suppression of p53.
  Cancer Cell, 18, 411-422.  
20448891 F.Campbell, J.P.Plante, T.A.Edwards, S.L.Warriner, and A.J.Wilson (2010).
N-alkylated oligoamide alpha-helical proteomimetics.
  Org Biomol Chem, 8, 2344-2351.  
20473303 F.Christ, A.Voet, A.Marchand, S.Nicolet, B.A.Desimmie, D.Marchand, D.Bardiot, N.J.Van der Veken, B.Van Remoortel, S.V.Strelkov, M.De Maeyer, P.Chaltin, and Z.Debyser (2010).
Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication.
  Nat Chem Biol, 6, 442-448.  
19941302 G.Funari, F.Domenici, L.Nardinocchi, R.Puca, G.D'Orazi, A.R.Bizzarri, and S.Cannistraro (2010).
Interaction of p53 with Mdm2 and azurin as studied by atomic force spectroscopy.
  J Mol Recognit, 23, 343-351.  
20490618 G.Hu, D.Wang, X.Liu, and Q.Zhang (2010).
A computational analysis of the binding model of MDM2 with inhibitors.
  J Comput Aided Mol Des, 24, 687-697.  
20708156 H.Inuzuka, A.Tseng, D.Gao, B.Zhai, Q.Zhang, S.Shaik, L.Wan, X.L.Ang, C.Mock, H.Yin, J.M.Stommel, S.Gygi, G.Lahav, J.Asara, Z.X.Xiao, W.G.Kaelin, J.W.Harper, and W.Wei (2010).
Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase.
  Cancer Cell, 18, 147-159.  
21075301 J.C.Marine (2010).
Pharmacological rescue of p53 in cancer therapy: widening the sensitive tumor spectrum by targeting MDMX.
  Cancer Cell, 18, 399-400.  
19811448 J.D.Amaral, A.R.Correia, C.J.Steer, C.M.Gomes, and C.M.Rodrigues (2010).
No evidence of direct binding between ursodeoxycholic acid and the p53 DNA-binding domain.
  Biosci Rep, 30, 359-364.  
21142860 J.D.Martinez (2010).
Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy.
  Future Oncol, 6, 1857-1862.  
20404136 J.Long, B.Parkin, P.Ouillette, D.Bixby, K.Shedden, H.Erba, S.Wang, and S.N.Malek (2010).
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.
  Blood, 116, 71-80.  
19910468 J.Phan, Z.Li, A.Kasprzak, B.Li, S.Sebti, W.Guida, E.Schönbrunn, and J.Chen (2010).
Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX.
  J Biol Chem, 285, 2174-2183.
PDB codes: 3jzo 3jzp 3jzq 3jzr 3jzs
20080776 J.Zhang, T.Nodzynski, A.Pencík, J.Rolcík, and J.Friml (2010).
PIN phosphorylation is sufficient to mediate PIN polarity and direct auxin transport.
  Proc Natl Acad Sci U S A, 107, 918-922.  
20498067 K.Ruzicka, L.C.Strader, A.Bailly, H.Yang, J.Blakeslee, L.Langowski, E.Nejedlá, H.Fujita, H.Itoh, K.Syono, J.Hejátko, W.M.Gray, E.Martinoia, M.Geisler, B.Bartel, A.S.Murphy, and J.Friml (2010).
Arabidopsis PIS1 encodes the ABCG37 transporter of auxinic compounds including the auxin precursor indole-3-butyric acid.
  Proc Natl Acad Sci U S A, 107, 10749-10753.  
20821791 L.K.Henchey, J.R.Porter, I.Ghosh, and P.S.Arora (2010).
High specificity in protein recognition by hydrogen-bond-surrogate α-helices: selective inhibition of the p53/MDM2 complex.
  Chembiochem, 11, 2104-2107.  
20660730 M.Liu, C.Li, M.Pazgier, C.Li, Y.Mao, Y.Lv, B.Gu, G.Wei, W.Yuan, C.Zhan, W.Y.Lu, and W.Lu (2010).
D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
  Proc Natl Acad Sci U S A, 107, 14321-14326.
PDB code: 3iwy
20639885 M.V.Poyurovsky, C.Katz, O.Laptenko, R.Beckerman, M.Lokshin, J.Ahn, I.J.Byeon, R.Gabizon, M.Mattia, A.Zupnick, L.M.Brown, A.Friedler, and C.Prives (2010).
The C terminus of p53 binds the N-terminal domain of MDM2.
  Nat Struct Mol Biol, 17, 982-989.  
19858117 P.Sun, Q.Y.Tian, J.Chen, and W.H.Zhang (2010).
Aluminium-induced inhibition of root elongation in Arabidopsis is mediated by ethylene and auxin.
  J Exp Bot, 61, 347-356.  
20205445 R.G.Coleman, and K.A.Sharp (2010).
Protein pockets: inventory, shape, and comparison.
  J Chem Inf Model, 50, 589-603.  
20479273 R.Kulikov, J.Letienne, M.Kaur, S.R.Grossman, J.Arts, and C.Blattner (2010).
Mdm2 facilitates the association of p53 with the proteasome.
  Proc Natl Acad Sci U S A, 107, 10038-10043.  
19955655 S.Araki, J.A.Eitel, C.N.Batuello, K.Bijangi-Vishehsaraei, X.J.Xie, D.Danielpour, K.E.Pollok, D.A.Boothman, and L.D.Mayo (2010).
TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer.
  J Clin Invest, 120, 290-302.  
  20516129 V.A.Belyi, P.Ak, E.Markert, H.Wang, W.Hu, A.Puzio-Kuter, and A.J.Levine (2010).
The origins and evolution of the p53 family of genes.
  Cold Spring Harb Perspect Biol, 2, a001198.  
20130056 W.Chen, I.B.Hilton, M.R.Staudt, C.E.Burd, and D.P.Dittmer (2010).
Distinct p53, p53:LANA, and LANA complexes in Kaposi's Sarcoma--associated Herpesvirus Lymphomas.
  J Virol, 84, 3898-3908.  
19952011 Y.Ugartechea-Chirino, R.Swarup, K.Swarup, B.Péret, M.Whitworth, M.Bennett, and S.Bougourd (2010).
The AUX1 LAX family of auxin influx carriers is required for the establishment of embryonic root cell organization in Arabidopsis thaliana.
  Ann Bot, 105, 277-289.  
20542919 Y.Zhang, J.Wang, Y.Yuan, W.Zhang, W.Guan, Z.Wu, C.Jin, H.Chen, L.Zhang, X.Yang, and F.He (2010).
Negative regulation of HDM2 to attenuate p53 degradation by ribosomal protein L26.
  Nucleic Acids Res, 38, 6544-6554.  
21213101 Z.Wang, and B.Li (2010).
Mdm2 links genotoxic stress and metabolism to p53.
  Protein Cell, 1, 1063-1072.  
  20165689 Z.Wang, and Y.Sun (2010).
Targeting p53 for Novel Anticancer Therapy.
  Transl Oncol, 3, 1.  
19408261 A.Grässlin, C.Amoreira, K.K.Baldridge, and J.A.Robinson (2009).
Thermodynamic and computational studies on the binding of p53-derived peptides and peptidomimetic inhibitors to HDM2.
  Chembiochem, 10, 1360-1368.  
19847292 A.K.Sharma, A.Ali, R.Gogna, A.K.Singh, and U.Pati (2009).
p53 Amino-terminus region (1-125) stabilizes and restores heat denatured p53 wild phenotype.
  PLoS One, 4, e7159.  
19286366 A.L.Okorokov, and E.V.Orlova (2009).
Structural biology of the p53 tumour suppressor.
  Curr Opin Struct Biol, 19, 197-202.  
19244339 A.Saha, M.Murakami, P.Kumar, B.Bajaj, K.Sims, and E.S.Robertson (2009).
Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2.
  J Virol, 83, 4652-4669.  
19334711 A.Shaginian, L.R.Whitby, S.Hong, I.Hwang, B.Farooqi, M.Searcey, J.Chen, P.K.Vogt, and D.L.Boger (2009).
Design, synthesis, and evaluation of an alpha-helix mimetic library targeting protein-protein interactions.
  J Am Chem Soc, 131, 5564-5572.  
19412530 B.Mészáros, I.Simon, and Z.Dosztányi (2009).
Prediction of protein binding regions in disordered proteins.
  PLoS Comput Biol, 5, e1000376.  
18824505 B.Titapiwatanakun, and A.S.Murphy (2009).
Post-transcriptional regulation of auxin transport proteins: cellular trafficking, protein phosphorylation, protein maturation, ubiquitination, and membrane composition.
  J Exp Bot, 60, 1093-1107.  
19188367 B.Wawrzynow, S.Pettersson, A.Zylicz, J.Bramham, E.Worrall, T.R.Hupp, and K.L.Ball (2009).
A function for the RING finger domain in the allosteric control of MDM2 conformation and activity.
  J Biol Chem, 284, 11517-11530.  
  19827079 C.Li, M.Pazgier, M.Liu, W.Y.Lu, and W.Lu (2009).
Apamin as a template for structure-based rational design of potent peptide activators of p53.
  Angew Chem Int Ed Engl, 48, 8712-8715.
PDB code: 3iux
19220000 C.W.Lee, M.Arai, M.A.Martinez-Yamout, H.J.Dyson, and P.E.Wright (2009).
Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP.
  Biochemistry, 48, 2115-2124.  
19245247 D.Missirlis, H.Khant, and M.Tirrell (2009).
Mechanisms of peptide amphiphile internalization by SJSA-1 cells in vitro.
  Biochemistry, 48, 3304-3314.  
19211253 E.A.Harker, D.S.Daniels, D.A.Guarracino, and A.Schepartz (2009).
Beta-peptides with improved affinity for hDM2 and hDMX.
  Bioorg Med Chem, 17, 2038-2046.  
19568783 E.G.Worrall, B.Wawrzynow, L.Worrall, M.Walkinshaw, K.L.Ball, and T.R.Hupp (2009).
Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif.
  J Chem Biol, 2, 113-129.  
19088336 E.W.Chehab, E.Eich, and J.Braam (2009).
Thigmomorphogenesis: a complex plant response to mechano-stimulation.
  J Exp Bot, 60, 43-56.  
19933326 F.Huang, S.Rajagopalan, G.Settanni, R.J.Marsh, D.A.Armoogum, N.Nicolaou, A.J.Bain, E.Lerner, E.Haas, L.Ying, and A.R.Fersht (2009).
Multiple conformations of full-length p53 detected with single-molecule fluorescence resonance energy transfer.
  Proc Natl Acad Sci U S A, 106, 20758-20763.  
19217391 H.Feng, L.M.Jenkins, S.R.Durell, R.Hayashi, S.J.Mazur, S.Cherry, J.E.Tropea, M.Miller, A.Wlodawer, E.Appella, and Y.Bai (2009).
Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation.
  Structure, 17, 202-210.
PDB code: 2k8f
19377511 H.Uhlmann-Schiffler, S.Kiermayer, and H.Stahl (2009).
The DEAD box protein Ddx42p modulates the function of ASPP2, a stimulator of apoptosis.
  Oncogene, 28, 2065-2073.  
19707204 J.A.Canner, M.Sobo, S.Ball, B.Hutzen, S.DeAngelis, W.Willis, A.W.Studebaker, K.Ding, S.Wang, D.Yang, and J.Lin (2009).
MI-63: a novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53.
  Br J Cancer, 101, 774-781.  
19266524 J.A.Robinson (2009).
Design of protein-protein interaction inhibitors based on protein epitope mimetics.
  Chembiochem, 10, 971-973.  
19357310 J.C.Ferreon, C.W.Lee, M.Arai, M.A.Martinez-Yamout, H.J.Dyson, and P.E.Wright (2009).
Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2.
  Proc Natl Acad Sci U S A, 106, 6591-6596.  
19153082 J.Kallen, A.Goepfert, A.Blechschmidt, A.Izaac, M.Geiser, G.Tavares, P.Ramage, P.Furet, K.Masuya, and J.Lisztwan (2009).
Crystal Structures of Human MdmX (HdmX) in Complex with p53 Peptide Analogues Reveal Surprising Conformational Changes.
  J Biol Chem, 284, 8812-8821.
PDB codes: 3fe7 3fea
19415930 J.Michel, E.A.Harker, J.Tirado-Rives, W.L.Jorgensen, and A.Schepartz (2009).
In Silico Improvement of beta3-peptide inhibitors of p53 x hDM2 and p53 x hDMX.
  J Am Chem Soc, 131, 6356-6357.  
19081927 K.Busschots, J.De Rijck, F.Christ, and Z.Debyser (2009).
In search of small molecules blocking interactions between HIV proteins and intracellular cofactors.
  Mol Biosyst, 5, 21-31.  
19246387 K.Ruzicka, M.Simásková, J.Duclercq, J.Petrásek, E.Zazímalová, S.Simon, J.Friml, M.C.Van Montagu, and E.Benková (2009).
Cytokinin regulates root meristem activity via modulation of the polar auxin transport.
  Proc Natl Acad Sci U S A, 106, 4284-4289.  
19121375 L.A.Holbrook, R.A.Butler, R.E.Cashon, and R.J.Van Beneden (2009).
Soft-shell clam (Mya arenaria) p53: a structural and functional comparison to human p53.
  Gene, 433, 81-87.  
19166313 L.M.Jenkins, H.Yamaguchi, R.Hayashi, S.Cherry, J.E.Tropea, M.Miller, A.Wlodawer, E.Appella, and S.J.Mazur (2009).
Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation.
  Biochemistry, 48, 1244-1255.  
19267375 M.Hintersteiner, T.Kimmerlin, G.Garavel, T.Schindler, R.Bauer, N.C.Meisner, J.M.Seifert, V.Uhl, and M.Auer (2009).
A highly potent and cellularly active beta-peptidic inhibitor of the p53/hDM2 interaction.
  Chembiochem, 10, 994-998.  
19753366 M.M.Madden, C.I.Rivera Vera, W.Song, and Q.Lin (2009).
Facile synthesis of stapled, structurally reinforced peptide helices via a photoinduced intramolecular 1,3-dipolar cycloaddition reaction.
  Chem Commun (Camb), (), 5588-5590.  
19966416 M.Miller, Z.Dauter, S.Cherry, J.E.Tropea, and A.Wlodawer (2009).
Structure of the Taz2 domain of p300: insights into ligand binding.
  Acta Crystallogr D Biol Crystallogr, 65, 1301-1308.
PDB code: 3io2
19519454 M.Miller (2009).
The importance of being flexible: the case of basic region leucine zipper transcriptional regulators.
  Curr Protein Pept Sci, 10, 244-269.  
19021159 M.Orzáez, A.Gortat, L.Mondragón, and E.Pérez-Payá (2009).
Peptides and peptide mimics as modulators of apoptotic pathways.
  ChemMedChem, 4, 146-160.  
19255450 M.Pazgier, M.Liu, G.Zou, W.Yuan, C.Li, C.Li, J.Li, J.Monbo, D.Zella, S.G.Tarasov, and W.Lu (2009).
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
  Proc Natl Acad Sci U S A, 106, 4665-4670.
PDB codes: 3eqs 3eqy
19147532 M.Wade, and G.M.Wahl (2009).
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
  Mol Cancer Res, 7, 1.  
20030851 N.Tageja, S.Padheye, P.Dandawate, A.Al-Katib, and R.M.Mohammad (2009).
New targets for the treatment of follicular lymphoma.
  J Hematol Oncol, 2, 50.  
19617345 P.Tsvetkov, N.Reuven, C.Prives, and Y.Shaul (2009).
Susceptibility of p53 unstructured N terminus to 20 S proteasomal degradation programs the stress response.
  J Biol Chem, 284, 26234-26242.  
20161293 R.C.Clark, S.Y.Lee, I.Hwang, M.Searcey, and D.L.Boger (2009).
Evaluation of Chlorofusin, its Seven Chromophore Diastereomers, and Key Analogues.
  Tetrahedron Lett, 50, 3151-3153.  
19642417 R.C.Clark, S.Y.Lee, M.Searcey, and D.L.Boger (2009).
The isolation, total synthesis and structure elucidation of chlorofusin, a natural product inhibitor of the p53-mDM2 protein-protein interaction.
  Nat Prod Rep, 26, 465-477.  
19774270 R.Guo, F.Fournier, P.M.Donaldson, E.M.Gardner, I.R.Gould, and D.R.Klug (2009).
Detection of complex formation and determination of intermolecular geometry through electrical anharmonic coupling of molecular vibrations using electron-vibration-vibration two-dimensional infrared spectroscopy.
  Phys Chem Chem Phys, 11, 8417-8421.  
19880322 R.Hayashi, D.Wang, T.Hara, J.A.Iera, S.R.Durell, and D.H.Appella (2009).
N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53.
  Bioorg Med Chem, 17, 7884-7893.  
19339067 R.L.van Montfort, and P.Workman (2009).
Structure-based design of molecular cancer therapeutics.
  Trends Biotechnol, 27, 315-328.  
19218448 S.Burge, D.P.Teufel, F.M.Townsley, S.M.Freund, M.Bycroft, and A.R.Fersht (2009).
Molecular basis of the interactions between the p73 N terminus and p300: effects on transactivation and modulation by phosphorylation.
  Proc Natl Acad Sci U S A, 106, 3142-3147.  
19402914 S.Fukuchi, K.Homma, Y.Minezaki, T.Gojobori, and K.Nishikawa (2009).
Development of an accurate classification system of proteins into structured and unstructured regions that uncovers novel structural domains: its application to human transcription factors.
  BMC Struct Biol, 9, 26.  
19958516 S.G.Dastidar, D.P.Lane, and C.S.Verma (2009).
Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100.
  BMC Bioinformatics, 10, S6.  
19176230 S.L.Quackenbush, A.Linton, C.D.Brewster, and J.Rovnak (2009).
Walleye dermal sarcoma virus rv-cyclin inhibits NF-kappaB-dependent transcription.
  Virology, 386, 55-60.  
19525231 S.Rajagopalan, A.Andreeva, D.P.Teufel, S.M.Freund, and A.R.Fersht (2009).
Interaction between the transactivation domain of p53 and PC4 exemplifies acidic activation domains as single-stranded DNA mimics.
  J Biol Chem, 284, 21728-21737.  
18834305 S.Shangary, and S.Wang (2009).
Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
  Annu Rev Pharmacol Toxicol, 49, 223-241.  
19928922 S.Yu, D.Qin, S.Shangary, J.Chen, G.Wang, K.Ding, D.McEachern, S.Qiu, Z.Nikolovska-Coleska, R.Miller, S.Kang, D.Yang, and S.Wang (2009).
Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
  J Med Chem, 52, 7970-7973.  
19066201 T.S.Wong, S.Rajagopalan, F.M.Townsley, S.M.Freund, M.Petrovich, D.Loakes, and A.R.Fersht (2009).
Physical and functional interactions between human mitochondrial single-stranded DNA-binding protein and tumour suppressor p53.
  Nucleic Acids Res, 37, 568-581.  
19633659 T.Shahian, G.M.Lee, A.Lazic, L.A.Arnold, P.Velusamy, C.M.Roels, R.K.Guy, and C.S.Craik (2009).
Inhibition of a viral enzyme by a small-molecule dimer disruptor.
  Nat Chem Biol, 5, 640-646.  
19580521 X.Cai, and Z.M.Yuan (2009).
Stochastic modeling and simulation of the p53-MDM2/MDMX loop.
  J Comput Biol, 16, 917-933.  
18410249 A.C.Joerger, and A.R.Fersht (2008).
Structural biology of the tumor suppressor p53.
  Annu Rev Biochem, 77, 557-582.  
18501203 A.Dömling (2008).
Small molecular weight protein-protein interaction antagonists: an insurmountable challenge?
  Curr Opin Chem Biol, 12, 281-291.  
18648687 A.I.Anzellotti, and N.P.Farrell (2008).
Zinc metalloproteins as medicinal targets.
  Chem Soc Rev, 37, 1629-1651.  
19096501 A.Tóth-Petróczy, C.J.Oldfield, I.Simon, Y.Takagi, A.K.Dunker, V.N.Uversky, and M.Fuxreiter (2008).
Malleable machines in transcription regulation: the mediator complex.
  PLoS Comput Biol, 4, e1000243.  
19043449 A.Vazquez, E.E.Bond, A.J.Levine, and G.L.Bond (2008).
The genetics of the p53 pathway, apoptosis and cancer therapy.
  Nat Rev Drug Discov, 7, 979-987.  
18366598 C.J.Oldfield, J.Meng, J.Y.Yang, M.Q.Yang, V.N.Uversky, and A.K.Dunker (2008).
Flexible nets: disorder and induced fit in the associations of p53 and 14-3-3 with their partners.
  BMC Genomics, 9, S1.  
18536020 D.F.Lowry, A.C.Hausrath, and G.W.Daughdrill (2008).
A robust approach for analyzing a heterogeneous structural ensemble.
  Proteins, 73, 918-928.  
17972286 D.F.Lowry, A.Stancik, R.M.Shrestha, and G.W.Daughdrill (2008).
Modeling the accessible conformations of the intrinsically unstructured transactivation domain of p53.
  Proteins, 71, 587-598.  
19738896 J.A.Lehman, J.A.Eitel, C.N.Batuello, and L.D.Mayo (2008).
Therapeutic considerations for Mdm2: not just a one trick pony.
  Expert Opin Drug Discov, 3, 1309-1321.  
18725320 J.A.Robinson, S.Demarco, F.Gombert, K.Moehle, and D.Obrecht (2008).
The design, structures and therapeutic potential of protein epitope mimetics.
  Drug Discov Today, 13, 944-951.  
18701455 J.B.Thoden, L.A.Ryan, R.J.Reece, and H.M.Holden (2008).
The interaction between an acidic transcriptional activator and its inhibitor. The molecular basis of Gal4p recognition by Gal80p.
  J Biol Chem, 283, 30266-30272.
PDB code: 3e1k
18306465 J.K.Yang (2008).
FLIP as an anti-cancer therapeutic target.
  Yonsei Med J, 49, 19-27.  
17206471 L.Jiang, Y.Ma, J.Wang, X.Tao, and D.Wei (2008).
The transduction of His-TAT-p53 fusion protein into the human osteogenic sarcoma cell line (Saos-2) and its influence on cell cycle arrest and apoptosis.
  Mol Biol Rep, 35, 1-8.  
17700533 L.M.Lau, J.K.Nugent, X.Zhao, and M.S.Irwin (2008).
HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
  Oncogene, 27, 997.  
19007437 M.D.Petroski (2008).
The ubiquitin system, disease, and drug discovery.
  BMC Biochem, 9, S7.  
18679808 M.G.Lerner, K.L.Meagher, and H.A.Carlson (2008).
Automated clustering of probe molecules from solvent mapping of protein surfaces: new algorithms applied to hot-spot mapping and structure-based drug design.
  J Comput Aided Mol Des, 22, 727-736.  
19160491 M.M.Candeias, L.Malbert-Colas, D.J.Powell, C.Daskalogianni, M.M.Maslon, N.Naski, K.Bourougaa, F.Calvo, and R.Fåhraeus (2008).
P53 mRNA controls p53 activity by managing Mdm2 functions.
  Nat Cell Biol, 10, 1098-1105.  
18354501 M.Okuda, A.Tanaka, M.Satoh, S.Mizuta, M.Takazawa, Y.Ohkuma, and Y.Nishimura (2008).
Structural insight into the TFIIE-TFIIH interaction: TFIIE and p53 share the binding region on TFIIH.
  EMBO J, 27, 1161-1171.
PDB codes: 2rnq 2rnr
18619997 M.S.Cortese, V.N.Uversky, and A.K.Dunker (2008).
Intrinsic disorder in scaffold proteins: getting more from less.
  Prog Biophys Mol Biol, 98, 85.  
18391200 M.Wells, H.Tidow, T.J.Rutherford, P.Markwick, M.R.Jensen, E.Mylonas, D.I.Svergun, M.Blackledge, and A.R.Fersht (2008).
Structure of tumor suppressor p53 and its intrinsically disordered N-terminal transactivation domain.
  Proc Natl Acad Sci U S A, 105, 5762-5767.  
18238895 N.Baptiste-Okoh, A.M.Barsotti, and C.Prives (2008).
A role for caspase 2 and PIDD in the process of p53-mediated apoptosis.
  Proc Natl Acad Sci U S A, 105, 1937-1942.  
  18949072 O.Sperandio, M.A.Miteva, K.Segers, G.A.Nicolaes, and B.O.Villoutreix (2008).
Screening Outside the Catalytic Site: Inhibition of Macromolecular Inter-actions Through Structure-Based Virtual Ligand Screening Experiments.
  Open Biochem J, 2, 29-37.  
18337510 P.Dhonukshe, I.Grigoriev, R.Fischer, M.Tominaga, D.G.Robinson, J.Hasek, T.Paciorek, J.Petrásek, D.Seifertová, R.Tejos, L.A.Meisel, E.Zazímalová, T.W.Gadella, Y.D.Stierhof, T.Ueda, K.Oiwa, A.Akhmanova, R.Brock, A.Spang, and J.Friml (2008).
Auxin transport inhibitors impair vesicle motility and actin cytoskeleton dynamics in diverse eukaryotes.
  Proc Natl Acad Sci U S A, 105, 4489-4494.  
17973336 P.S.Ghosh, G.Han, B.Erdogan, O.Rosado, and V.M.Rotello (2008).
Binding of nanoparticle receptors to peptide alpha-helices using amino acid-functionalized nanoparticles.
  J Pept Sci, 14, 134-138.  
18712872 R.C.Clark, S.Y.Lee, and D.L.Boger (2008).
Total synthesis of chlorofusin, its seven chromophore diastereomers, and key partial structures.
  J Am Chem Soc, 130, 12355-12369.  
18809412 S.G.Sivakolundu, A.Nourse, S.Moshiach, B.Bothner, C.Ashley, J.Satumba, J.Lahti, and R.W.Kriwacki (2008).
Intrinsically unstructured domains of Arf and Hdm2 form bimolecular oligomeric structures in vitro and in vivo.
  J Mol Biol, 384, 240-254.  
19012295 S.Kneissl, E.J.Loveridge, C.Williams, M.P.Crump, and R.K.Allemann (2008).
Photocontrollable peptide-based switches target the anti-apoptotic protein Bcl-xL.
  Chembiochem, 9, 3046-3054.  
19012502 S.Patel, and M.R.Player (2008).
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
  Expert Opin Investig Drugs, 17, 1865-1882.  
18316739 S.Shangary, D.Qin, D.McEachern, M.Liu, R.S.Miller, S.Qiu, Z.Nikolovska-Coleska, K.Ding, G.Wang, J.Chen, D.Bernard, J.Zhang, Y.Lu, Q.Gu, R.B.Shah, K.J.Pienta, X.Ling, S.Kang, M.Guo, Y.Sun, D.Yang, and S.Wang (2008).
Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition.
  Proc Natl Acad Sci U S A, 105, 3933-3938.  
18566224 S.Shangary, K.Ding, S.Qiu, Z.Nikolovska-Coleska, J.A.Bauer, M.Liu, G.Wang, Y.Lu, D.McEachern, D.Bernard, C.R.Bradford, T.E.Carey, and S.Wang (2008).
Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
  Mol Cancer Ther, 7, 1533-1542.  
18765522 S.Shangary, and S.Wang (2008).
Targeting the MDM2-p53 interaction for cancer therapy.
  Clin Cancer Res, 14, 5318-5324.  
18573080 V.N.Uversky, C.J.Oldfield, and A.K.Dunker (2008).
Intrinsically disordered proteins in human diseases: introducing the D2 concept.
  Annu Rev Biophys, 37, 215-246.  
17401432 A.C.Joerger, and A.R.Fersht (2007).
Structure-function-rescue: the diverse nature of common p53 cancer mutants.
  Oncogene, 26, 2226-2242.  
17121789 C.E.Petre, S.H.Sin, and D.P.Dittmer (2007).
Functional p53 signaling in Kaposi's sarcoma-associated herpesvirus lymphomas: implications for therapy.
  J Virol, 81, 1912-1922.  
17438265 D.P.Teufel, S.M.Freund, M.Bycroft, and A.R.Fersht (2007).
Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53.
  Proc Natl Acad Sci U S A, 104, 7009-7014.  
17903248 E.Villiard, H.Brinkmann, O.Moiseeva, F.A.Mallette, G.Ferbeyre, and S.Roy (2007).
Urodele p53 tolerates amino acid changes found in p53 variants linked to human cancer.
  BMC Evol Biol, 7, 180.  
17302414 H.F.Chen, and R.Luo (2007).
Binding induced folding in p53-MDM2 complex.
  J Am Chem Soc, 129, 2930-2937.  
17620598 H.Tidow, R.Melero, E.Mylonas, S.M.Freund, J.G.Grossmann, J.M.Carazo, D.I.Svergun, M.Valle, and A.R.Fersht (2007).
Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex.
  Proc Natl Acad Sci U S A, 104, 12324-12329.  
17391014 H.Xie, S.Vucetic, L.M.Iakoucheva, C.J.Oldfield, A.K.Dunker, V.N.Uversky, and Z.Obradovic (2007).
Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with long disordered regions.
  J Proteome Res, 6, 1882-1898.  
18075579 J.A.Wells, and C.L.McClendon (2007).
Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.
  Nature, 450, 1001-1009.  
17427181 J.K.Murray, and S.H.Gellman (2007).
Targeting protein-protein interactions: lessons from p53/MDM2.
  Biopolymers, 88, 657-686.  
17264933 J.M.Davis, L.K.Tsou, and A.D.Hamilton (2007).
Synthetic non-peptide mimetics of alpha-helices.
  Chem Soc Rev, 36, 326-334.  
17822515 L.A.Valentino, N.Hakobyan, N.Rodriguez, and W.K.Hoots (2007).
Pathogenesis of haemophilic synovitis: experimental studies on blood-induced joint damage.
  Haemophilia, 13, 10-13.  
17126603 L.T.Vassilev (2007).
MDM2 inhibitors for cancer therapy.
  Trends Mol Med, 13, 23-31.  
17636030 M.Ginsberg, E.Czeko, P.Müller, Z.Ren, X.Chen, and J.E.Darnell (2007).
Amino acid residues required for physical and cooperative transcriptional interaction of STAT3 and AP-1 proteins c-Jun and c-Fos.
  Mol Cell Biol, 27, 6300-6308.  
17334395 M.P.Deyoung, and L.W.Ellisen (2007).
p63 and p73 in human cancer: defining the network.
  Oncogene, 26, 5169-5183.  
17170710 M.V.Poyurovsky, C.Priest, A.Kentsis, K.L.Borden, Z.Q.Pan, N.Pavletich, and C.Prives (2007).
The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity.
  EMBO J, 26, 90.  
17149774 N.Arden, B.S.Majors, S.H.Ahn, G.Oyler, and M.J.Betenbaugh (2007).
Inhibiting the apoptosis pathway using MDM2 in mammalian cell cultures.
  Biotechnol Bioeng, 97, 601-614.  
17609779 P.S.Ghosh, A.Verma, and V.M.Rotello (2007).
Binding and templation of nanoparticle receptors to peptide alpha-helices through surface recognition.
  Chem Commun (Camb), (), 2796-2798.  
17335006 P.Vise, B.Baral, A.Stancik, D.F.Lowry, and G.W.Daughdrill (2007).
Identifying long-range structure in the intrinsically unstructured transactivation domain of p53.
  Proteins, 67, 526-530.  
17598915 S.Yaklichkin, A.Vekker, S.Stayrook, M.Lewis, and D.S.Kessler (2007).
Prevalence of the EH1 Groucho interaction motif in the metazoan Fox family of transcriptional regulators.
  BMC Genomics, 8, 201.  
17401426 T.Iwakuma, and G.Lozano (2007).
Crippling p53 activities via knock-in mutations in mouse models.
  Oncogene, 26, 2177-2184.  
  18007958 W.B.Bowne, J.Michl, M.H.Bluth, M.E.Zenilman, and M.R.Pincus (2007).
Novel peptides from the RAS-p21 and p53 proteins for the treatment of cancer.
  Cancer Ther, 5, 331-344.  
17457521 X.Long, M.J.Goldenthal, and J.Marín-García (2007).
Oxidative stress enhances phosphorylation of p53 in neonatal rat cardiomyocytes.
  Mol Cell Biochem, 303, 167-174.  
17973494 Y.Cheng, C.J.Oldfield, J.Meng, P.Romero, V.N.Uversky, and A.K.Dunker (2007).
Mining alpha-helix-forming molecular recognition features with cross species sequence alignments.
  Biochemistry, 46, 13468-13477.  
17053786 A.L.Okorokov, M.B.Sherman, C.Plisson, V.Grinkevich, K.Sigmundsson, G.Selivanova, J.Milner, and E.V.Orlova (2006).
The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity.
  EMBO J, 25, 5191-5200.  
16782868 A.Valbuena, F.M.Vega, S.Blanco, and P.A.Lazo (2006).
p53 downregulates its activating vaccinia-related kinase 1, forming a new autoregulatory loop.
  Mol Cell Biol, 26, 4782-4793.  
16732328 A.VanderBorght, A.Valckx, J.Van Dun, T.Grand-Perret, S.De Schepper, J.Vialard, M.Janicot, and J.Arts (2006).
Effect of an hdm-2 antagonist peptide inhibitor on cell cycle progression in p53-deficient H1299 human lung carcinoma cells.
  Oncogene, 25, 6672-6677.  
16452164 C.C.Harris (2006).
Protein-protein interactions for cancer therapy.
  Proc Natl Acad Sci U S A, 103, 1659-1660.  
16461914 D.B.Veprintsev, S.M.Freund, A.Andreeva, S.E.Rutledge, H.Tidow, J.M.Cañadillas, C.M.Blair, and A.R.Fersht (2006).
Core domain interactions in full-length p53 in solution.
  Proc Natl Acad Sci U S A, 103, 2115-2119.  
17009316 D.C.Fry (2006).
Protein-protein interactions as targets for small molecule drug discovery.
  Biopolymers, 84, 535-552.  
16278824 D.Hamroun, S.Kato, C.Ishioka, M.Claustres, C.Béroud, and T.Soussi (2006).
The UMD TP53 database and website: update and revisions.
  Hum Mutat, 27, 14-20.  
16635809 D.Jung, Y.Choi, and M.Uesugi (2006).
Small organic molecules that modulate gene transcription.
  Drug Discov Today, 11, 452-457.  
16444738 D.M.Bustos, and A.A.Iglesias (2006).
Intrinsic disorder is a key characteristic in partners that bind 14-3-3 proteins.
  Proteins, 63, 35-42.  
16575406 G.M.Wahl (2006).
Mouse bites dogma: how mouse models are changing our views of how P53 is regulated in vivo.
  Cell Death Differ, 13, 973-983.  
16816840 G.Nalepa, M.Rolfe, and J.W.Harper (2006).
Drug discovery in the ubiquitin-proteasome system.
  Nat Rev Drug Discov, 5, 596-613.  
16432196 G.W.Yu, S.Rudiger, D.Veprintsev, S.Freund, M.R.Fernandez-Fernandez, and A.R.Fersht (2006).
The central region of HDM2 provides a second binding site for p53.
  Proc Natl Acad Sci U S A, 103, 1227-1232.  
16819755 H.D.Arndt (2006).
Small molecule modulators of transcription.
  Angew Chem Int Ed Engl, 45, 4552-4560.  
16470212 H.Sauthoff, T.Pipiya, S.Chen, S.Heitner, J.Cheng, Y.Q.Huang, W.N.Rom, and J.G.Hay (2006).
Modification of the p53 transgene of a replication-competent adenovirus prevents mdm2- and E1b-55kD-mediated degradation of p53.
  Cancer Gene Ther, 13, 686-695.  
16925948 I.R.Watson, and M.S.Irwin (2006).
Ubiquitin and ubiquitin-like modifications of the p53 family.
  Neoplasia, 8, 655-666.  
16397877 J.A.Kritzer, R.Zutshi, M.Cheah, F.A.Ran, R.Webman, T.M.Wongjirad, and A.Schepartz (2006).
Miniature protein inhibitors of the p53-hDM2 interaction.
  Chembiochem, 7, 29-31.  
20141510 J.Deng, R.Dayam, and N.Neamati (2006).
Patented small molecule inhibitors of p53-MDM2 interaction.
  Expert Opin Ther Pat, 16, 165-188.  
16734424 J.Liu, N.B.Perumal, C.J.Oldfield, E.W.Su, V.N.Uversky, and A.K.Dunker (2006).
Intrinsic disorder in transcription factors.
  Biochemistry, 45, 6873-6888.  
16688716 J.Michl, B.Scharf, A.Schmidt, C.Huynh, R.Hannan, H.von Gizycki, F.K.Friedman, P.Brandt-Rauf, R.L.Fine, and M.R.Pincus (2006).
PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo.
  Int J Cancer, 119, 1577-1585.  
16557267 K.G.Wiman (2006).
Strategies for therapeutic targeting of the p53 pathway in cancer.
  Cell Death Differ, 13, 921-926.  
16817233 L.M.Espinoza-Fonseca, and J.G.Trujillo-Ferrara (2006).
Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations.
  Biopolymers, 83, 365-373.  
17054774 L.O.Baumbusch, S.Myhre, A.Langerød, A.Bergamaschi, S.B.Geisler, P.E.Lønning, W.Deppert, I.Dornreiter, and A.L.Børresen-Dale (2006).
Expression of full-length p53 and its isoform Deltap53 in breast carcinomas in relation to mutation status and clinical parameters.
  Mol Cancer, 5, 47.  
16983711 L.Römer, C.Klein, A.Dehner, H.Kessler, and J.Buchner (2006).
p53--a natural cancer killer: structural insights and therapeutic concepts.
  Angew Chem Int Ed Engl, 45, 6440-6460.  
16611213 M.D.Cummings, C.Schubert, D.J.Parks, R.R.Calvo, L.V.LaFrance, J.Lattanze, K.L.Milkiewicz, and T.Lu (2006).
Substituted 1,4-benzodiazepine-2,5-diones as alpha-helix mimetic antagonists of the HDM2-p53 protein-protein interaction.
  Chem Biol Drug Des, 67, 201-205.  
16402859 M.Hu, L.Gu, M.Li, P.D.Jeffrey, W.Gu, and Y.Shi (2006).
Structural basis of competitive recognition of p53 and MDM2 by HAUSP/USP7: implications for the regulation of the p53-MDM2 pathway.
  PLoS Biol, 4, e27.
PDB codes: 2f1w 2f1x 2f1y 2f1z
16983332 M.M.Candeias, D.J.Powell, E.Roubalova, S.Apcher, K.Bourougaa, B.Vojtesek, H.Bruzzoni-Giovanelli, and R.Fåhraeus (2006).
Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation.
  Oncogene, 25, 6936-6947.  
16807229 N.Kantarci, P.Doruker, and T.Haliloglu (2006).
Cooperative fluctuations point to the dimerization interface of p53 core domain.
  Biophys J, 91, 421-432.  
16331262 N.Li, H.Li, P.Cherukuri, S.Farzan, D.C.Harmes, and J.DiRenzo (2006).
TA-p63-gamma regulates expression of DeltaN-p63 in a manner that is sensitive to p53.
  Oncogene, 25, 2349-2359.  
16892375 P.Chène (2006).
Drugs targeting protein-protein interactions.
  ChemMedChem, 1, 400-411.  
16793543 P.Di Lello, L.M.Jenkins, T.N.Jones, B.D.Nguyen, T.Hara, H.Yamaguchi, J.D.Dikeakos, E.Appella, P.Legault, and J.G.Omichinski (2006).
Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53.
  Mol Cell, 22, 731-740.
PDB code: 2gs0
19617922 P.M.Fischer (2006).
Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53-HDM2 Protein-Protein Interaction.
  Int J Pept Res Ther, 12, 3.  
16493654 P.Radivojac, S.Vucetic, T.R.O'Connor, V.N.Uversky, Z.Obradovic, and A.K.Dunker (2006).
Calmodulin signaling: analysis and prediction of a disorder-dependent molecular recognition.
  Proteins, 63, 398-410.  
16511824 R.Fasan, R.L.Dias, K.Moehle, O.Zerbe, D.Obrecht, P.R.Mittl, M.G.Grütter, and J.A.Robinson (2006).
Structure-activity studies in a family of beta-hairpin protein epitope mimetic inhibitors of the p53-HDM2 protein-protein interaction.
  Chembiochem, 7, 515-526.
PDB code: 2axi
16704422 S.Blanco, L.Klimcakova, F.M.Vega, and P.A.Lazo (2006).
The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms determines their different effect on p53 stability in tumour cell lines.
  FEBS J, 273, 2487-2504.  
16849232 S.Fletcher, and A.D.Hamilton (2006).
Targeting protein-protein interactions by rational design: mimicry of protein surfaces.
  J R Soc Interface, 3, 215-233.  
16474381 T.R.Brummelkamp, A.W.Fabius, J.Mullenders, M.Madiredjo, A.Velds, R.M.Kerkhoven, R.Bernards, and R.L.Beijersbergen (2006).
An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors.
  Nat Chem Biol, 2, 202-206.  
16876893 Y.Cheng, T.LeGall, C.J.Oldfield, J.P.Mueller, Y.Y.Van, P.Romero, M.S.Cortese, V.N.Uversky, and A.K.Dunker (2006).
Rational drug design via intrinsically disordered protein.
  Trends Biotechnol, 24, 435-442.  
16917930 Y.L.Yip, V.Zoete, H.Scheib, and O.Michielin (2006).
Structural assessment of single amino acid mutations: application to TP53 function.
  Hum Mutat, 27, 926-937.  
16925947 Y.Sun (2006).
E3 ubiquitin ligases as cancer targets and biomarkers.
  Neoplasia, 8, 645-654.  
16218947 A.K.Dunker, M.S.Cortese, P.Romero, L.M.Iakoucheva, and V.N.Uversky (2005).
Flexible nets. The roles of intrinsic disorder in protein interaction networks.
  FEBS J, 272, 5129-5148.  
16204849 B.Ma, Y.Pan, K.Gunasekaran, O.Keskin, R.B.Venkataraghavan, A.J.Levine, and R.Nussinov (2005).
The contribution of the Trp/Met/Phe residues to physical interactions of p53 with cellular proteins.
  Phys Biol, 2, S56-S66.  
15738397 B.Ma, Y.Pan, K.Gunasekaran, R.B.Venkataraghavan, A.J.Levine, and R.Nussinov (2005).
Comparison of the protein-protein interfaces in the p53-DNA crystal structures: towards elucidation of the biological interface.
  Proc Natl Acad Sci U S A, 102, 3988-3993.  
15789434 C.J.Oldfield, E.L.Ulrich, Y.Cheng, A.K.Dunker, and J.L.Markley (2005).
Addressing the intrinsic disorder bottleneck in structural proteomics.
  Proteins, 59, 444-453.  
16122970 C.Y.Majmudar, and A.K.Mapp (2005).
Chemical approaches to transcriptional regulation.
  Curr Opin Chem Biol, 9, 467-474.  
16283145 D.C.Fry, and L.T.Vassilev (2005).
Targeting protein-protein interactions for cancer therapy.
  J Mol Med, 83, 955-963.  
16869788 D.P.Lane (2005).
Exploiting the p53 pathway for the diagnosis and therapy of human cancer.
  Cold Spring Harb Symp Quant Biol, 70, 489-497.  
16234232 E.Bochkareva, L.Kaustov, A.Ayed, G.S.Yi, Y.Lu, A.Pineda-Lucena, J.C.Liao, A.L.Okorokov, J.Milner, C.H.Arrowsmith, and A.Bochkarev (2005).
Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A.
  Proc Natl Acad Sci U S A, 102, 15412-15417.
PDB codes: 2b29 2b3g
15643668 G.Lozano, and G.P.Zambetti (2005).
What have animal models taught us about the p53 pathway?
  J Pathol, 205, 206-220.  
15757449 H.B.Newton (2005).
Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway.
  Expert Rev Anticancer Ther, 5, 177-191.  
15765497 H.Yin, G.I.Lee, H.S.Park, G.A.Payne, J.M.Rodriguez, S.M.Sebti, and A.D.Hamilton (2005).
Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction.
  Angew Chem Int Ed Engl, 44, 2704-2707.  
15988026 H.Ying, D.L.Chang, H.Zheng, F.McKeon, and Z.X.Xiao (2005).
DNA-binding and transactivation activities are essential for TAp63 protein degradation.
  Mol Cell Biol, 25, 6154-6164.  
15505803 H.Zhong, and H.A.Carlson (2005).
Computational studies and peptidomimetic design for the human p53-MDM2 complex.
  Proteins, 58, 222-234.  
15783163 J.A.Kritzer, M.E.Hodsdon, and A.Schepartz (2005).
Solution structure of a beta-peptide ligand for hDM2.
  J Am Chem Soc, 127, 4118-4119.  
16231906 J.A.Kritzer, N.W.Luedtke, E.A.Harker, and A.Schepartz (2005).
A rapid library screen for tailoring beta-peptide structure and function.
  J Am Chem Soc, 127, 14584-14585.  
15582447 J.A.Kritzer, O.M.Stephens, D.A.Guarracino, S.K.Reznik, and A.Schepartz (2005).
beta-Peptides as inhibitors of protein-protein interactions.
  Bioorg Med Chem, 13, 11-16.  
15973758 J.K.Lum, and A.K.Mapp (2005).
Artificial transcriptional activation domains.
  Chembiochem, 6, 1311-1315.  
16022282 K.K.Ford, J.A.Mack, and R.J.O'Neill (2005).
Multiple independent pseudogene derivations indicate increased instability of the Mdm2 locus in Mus caroli.
  Mol Biol Rep, 32, 95.  
  16174299 L.M.Espinoza-Fonseca (2005).
Targeting MDM2 by the small molecule RITA: towards the development of new multi-target drugs against cancer.
  Theor Biol Med Model, 2, 38.  
15939335 M.Arkin (2005).
Protein-protein interactions and cancer: small molecules going in for the kill.
  Curr Opin Chem Biol, 9, 317-324.  
16270059 M.Krajewski, P.Ozdowy, L.D'Silva, U.Rothweiler, and T.A.Holak (2005).
NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro.
  Nat Med, 11, 1135.  
15824059 P.D.Vise, B.Baral, A.J.Latos, and G.W.Daughdrill (2005).
NMR chemical shift and relaxation measurements provide evidence for the coupled folding and binding of the p53 transactivation domain.
  Nucleic Acids Res, 33, 2061-2077.  
15838523 S.L.Harris, and A.J.Levine (2005).
The p53 pathway: positive and negative feedback loops.
  Oncogene, 24, 2899-2908.  
15803155 S.Neidle, and D.E.Thurston (2005).
Chemical approaches to the discovery and development of cancer therapies.
  Nat Rev Cancer, 5, 285-296.  
16239906 S.W.Fesik (2005).
Promoting apoptosis as a strategy for cancer drug discovery.
  Nat Rev Cancer, 5, 876-885.  
16094605 V.N.Uversky, C.J.Oldfield, and A.K.Dunker (2005).
Showing your ID: intrinsic disorder as an ID for recognition, regulation and cell signaling.
  J Mol Recognit, 18, 343-384.  
15819625 W.T.Heyken, A.Repenning, J.Kumme, and H.J.Schüller (2005).
Constitutive expression of yeast phospholipid biosynthetic genes by variants of Ino2 activator defective for interaction with Opi1 repressor.
  Mol Microbiol, 56, 696-707.  
16243710 Y.Levav-Cohen, S.Haupt, and Y.Haupt (2005).
Mdm2 in growth signaling and cancer.
  Growth Factors, 23, 183-192.  
  15452548 C.Klein, and L.T.Vassilev (2004).
Targeting the p53-MDM2 interaction to treat cancer.
  Br J Cancer, 91, 1415-1419.  
15572782 C.P.Barrett, B.A.Hall, and M.E.Noble (2004).
Dynamite: a simple way to gain insight into protein motions.
  Acta Crystallogr D Biol Crystallogr, 60, 2280-2287.  
15343266 D.MacPherson, J.Kim, T.Kim, B.K.Rhee, C.T.Van Oostrom, R.A.DiTullio, M.Venere, T.D.Halazonetis, R.Bronson, A.De Vries, M.Fleming, and T.Jacks (2004).
Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23.
  EMBO J, 23, 3689-3699.  
15542844 F.M.Vega, A.Sevilla, and P.A.Lazo (2004).
p53 Stabilization and accumulation induced by human vaccinia-related kinase 1.
  Mol Cell Biol, 24, 10366-10380.  
15353804 L.D.Walensky, A.L.Kung, I.Escher, T.J.Malia, S.Barbuto, R.D.Wright, G.Wagner, G.L.Verdine, and S.J.Korsmeyer (2004).
Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix.
  Science, 305, 1466-1470.  
15558054 N.Issaeva, P.Bozko, M.Enge, M.Protopopova, L.G.Verhoef, M.Masucci, A.Pramanik, and G.Selivanova (2004).
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.
  Nat Med, 10, 1321-1328.  
15526327 N.Sunder-Plassmann, and A.Giannis (2004).
Novel activators of the tumour suppressor p53.
  Chembiochem, 5, 1635-1637.  
15565587 P.Gervaz, P.Bucher, and P.Morel (2004).
Two colons-two cancers: paradigm shift and clinical implications.
  J Surg Oncol, 88, 261-266.  
15219971 P.M.Fischer, and D.P.Lane (2004).
Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?
  Trends Pharmacol Sci, 25, 343-346.  
15357922 S.Löfås (2004).
Optimizing the hit-to-lead process using SPR analysis.
  Assay Drug Dev Technol, 2, 407-415.  
14512226 A.Caflisch (2003).
Folding for binding or binding for folding?
  Trends Biotechnol, 21, 423-425.  
12732728 B.D.Nguyen, K.L.Abbott, K.Potempa, M.S.Kobor, J.Archambault, J.Greenblatt, P.Legault, and J.G.Omichinski (2003).
NMR structure of a complex containing the TFIIF subunit RAP74 and the RNA polymerase II carboxyl-terminal domain phosphatase FCP1.
  Proc Natl Acad Sci U S A, 100, 5688-5693.
PDB code: 1onv
12612084 B.He, and E.M.Wilson (2003).
Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs.
  Mol Cell Biol, 23, 2135-2150.  
12944097 B.R.Wong, F.Parlati, K.Qu, S.Demo, T.Pray, J.Huang, D.G.Payan, and M.K.Bennett (2003).
Drug discovery in the ubiquitin regulatory pathway.
  Drug Discov Today, 8, 746-754.  
14612423 D.Dornan, H.Shimizu, L.Burch, A.J.Smith, and T.R.Hupp (2003).
The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53.
  Mol Cell Biol, 23, 8846-8861.  
12556205 H.K.Sluss, and S.N.Jones (2003).
Analysing p53 tumour suppressor functions in mice.
  Expert Opin Ther Targets, 7, 89-99.  
12877998 H.Shimizu, and T.R.Hupp (2003).
Intrasteric regulation of MDM2.
  Trends Biochem Sci, 28, 346-349.  
12670539 J.L.Naffin, Y.Han, H.J.Olivos, M.M.Reddy, T.Sun, and T.Kodadek (2003).
Immobilized peptides as high-affinity capture agents for self-associating proteins.
  Chem Biol, 10, 251-259.  
12552135 M.A.McCoy, J.J.Gesell, M.M.Senior, and D.F.Wyss (2003).
Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation.
  Proc Natl Acad Sci U S A, 100, 1645-1648.  
12972634 M.Overholtzer, P.H.Rao, R.Favis, X.Y.Lu, M.B.Elowitz, F.Barany, M.Ladanyi, R.Gorlick, and A.J.Levine (2003).
The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability.
  Proc Natl Acad Sci U S A, 100, 11547-11552.  
12856773 M.Yazawa, A.Setoguchi, S.H.Hong, R.Uyama, T.Nakagawa, N.Kanaya, R.Nishimura, N.Sasaki, K.Masuda, K.Ohno, and H.Tsujimoto (2003).
Effect of an adenoviral vector that expresses the canine p53 gene on cell growth of canine osteosarcoma and mammary adenocarcinoma cell lines.
  Am J Vet Res, 64, 880-888.  
12563309 P.Chène (2003).
Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.
  Nat Rev Cancer, 3, 102-109.  
12936988 R.E.Benson, E.B.Gottlin, D.J.Christensen, and P.T.Hamilton (2003).
Intracellular expression of Peptide fusions for demonstration of protein essentiality in bacteria.
  Antimicrob Agents Chemother, 47, 2875-2881.  
12824398 R.Linding, R.B.Russell, V.Neduva, and T.J.Gibson (2003).
GlobPlot: Exploring protein sequences for globularity and disorder.
  Nucleic Acids Res, 31, 3701-3708.  
12761890 R.Rallapalli, G.Strachan, R.S.Tuan, and D.J.Hall (2003).
Identification of a domain within MDMX-S that is responsible for its high affinity interaction with p53 and high-level expression in mammalian cells.
  J Cell Biochem, 89, 563-575.  
12502741 C.Lee, J.H.Chang, H.S.Lee, and Y.Cho (2002).
Structural basis for the recognition of the E2F transactivation domain by the retinoblastoma tumor suppressor.
  Genes Dev, 16, 3199-3212.
PDB code: 1n4m
12487430 G.Varadi, and L.Otvos (2002).
Synthesis of complex phosphopeptides as mimics of p53 functional domains.
  J Pept Sci, 8, 621-633.  
  12071800 H.Abdoul-Carime, S.Cecchini, and L.Sanche (2002).
Alteration of protein structure induced by low-energy (<18 eV) electrons. I. The peptide and disulfide bridges.
  Radiat Res, 158, 23-31.  
11839490 H.J.Dyson, and P.E.Wright (2002).
Coupling of folding and binding for unstructured proteins.
  Curr Opin Struct Biol, 12, 54-60.  
11960694 K.H.Vousden (2002).
Activation of the p53 tumor suppressor protein.
  Biochim Biophys Acta, 1602, 47-59.  
  11940455 K.Jessen-Eller, J.A.Kreiling, G.S.Begley, M.E.Steele, C.W.Walker, R.E.Stephens, and C.L.Reinisch (2002).
A new invertebrate member of the p53 gene family is developmentally expressed and responds to polychlorinated biphenyls.
  Environ Health Perspect, 110, 377-385.  
11983168 K.Okamoto, H.Li, M.R.Jensen, T.Zhang, Y.Taya, S.S.Thorgeirsson, and C.Prives (2002).
Cyclin G recruits PP2A to dephosphorylate Mdm2.
  Mol Cell, 9, 761-771.  
11859876 M.Hori, J.Shimazaki, S.Inagawa, M.Itabashi, and M.Hori (2002).
Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer.
  Breast Cancer Res Treat, 71, 77-83.  
11891322 T.Berg, S.B.Cohen, J.Desharnais, C.Sonderegger, D.J.Maslyar, J.Goldberg, D.L.Boger, and P.K.Vogt (2002).
Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts.
  Proc Natl Acad Sci U S A, 99, 3830-3835.  
12381794 T.Kortemme, and D.Baker (2002).
A simple physical model for binding energy hot spots in protein-protein complexes.
  Proc Natl Acad Sci U S A, 99, 14116-14121.  
12064467 V.Bazan, M.Migliavacca, C.Tubiolo, M.Macaluso, I.Zanna, S.Corsale, A.Amato, V.Calò, G.Dardanoni, V.Morello, M.La Farina, I.Albanese, R.M.Tomasino, N.Gebbia, and A.Russo (2002).
Have p53 gene mutations and protein expression a different biological significance in colorectal cancer?
  J Cell Physiol, 191, 237-246.  
12032546 Y.Yin, C.W.Stephen, M.G.Luciani, and R.Fåhraeus (2002).
p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products.
  Nat Cell Biol, 4, 462-467.  
12446779 Z.Serber, H.C.Lai, A.Yang, H.D.Ou, M.S.Sigal, A.E.Kelly, B.D.Darimont, P.H.Duijf, H.Van Bokhoven, F.McKeon, and V.Dötsch (2002).
A C-terminal inhibitory domain controls the activity of p63 by an intramolecular mechanism.
  Mol Cell Biol, 22, 8601-8611.  
11909939 Z.Wu, J.Earle, S.Saito, C.W.Anderson, E.Appella, and Y.Xu (2002).
Mutation of mouse p53 Ser23 and the response to DNA damage.
  Mol Cell Biol, 22, 2441-2449.  
11524676 A.Ayed, F.A.Mulder, G.S.Yi, Y.Lu, L.E.Kay, and C.H.Arrowsmith (2001).
Latent and active p53 are identical in conformation.
  Nat Struct Biol, 8, 756-760.  
11738175 A.G.Cochran (2001).
Protein-protein interfaces: mimics and inhibitors.
  Curr Opin Chem Biol, 5, 654-659.  
11336713 C.Gieffers, P.Dube, J.R.Harris, H.Stark, and J.M.Peters (2001).
Three-dimensional structure of the anaphase-promoting complex.
  Mol Cell, 7, 907-913.  
11258888 C.H.Henkels, J.C.Kurz, C.A.Fierke, and T.G.Oas (2001).
Linked folding and anion binding of the Bacillus subtilis ribonuclease P protein.
  Biochemistry, 40, 2777-2789.  
11583620 C.H.Lin, B.J.Hare, G.Wagner, S.C.Harrison, T.Maniatis, and E.Fraenkel (2001).
A small domain of CBP/p300 binds diverse proteins: solution structure and functional studies.
  Mol Cell, 8, 581-590.
PDB code: 1jjs
11484225 C.R.Zetina (2001).
A conserved helix-unfolding motif in the naturally unfolded proteins.
  Proteins, 44, 479-483.  
11781586 G.M.Wahl, and A.M.Carr (2001).
The evolution of diverse biological responses to DNA damage: insights from yeast and p53.
  Nat Cell Biol, 3, E277-E286.  
11243896 J.M.Pipas, and A.J.Levine (2001).
Role of T antigen interactions with p53 in tumorigenesis.
  Semin Cancer Biol, 11, 23-30.  
11359905 J.T.Zilfou, W.H.Hoffman, M.Sank, D.L.George, and M.Murphy (2001).
The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation.
  Mol Cell Biol, 21, 3974-3985.  
11714921 K.Dutta, A.Alexandrov, H.Huang, and S.M.Pascal (2001).
pH-induced folding of an apoptotic coiled coil.
  Protein Sci, 10, 2531-2540.  
11179228 K.Melcher, and H.E.Xu (2001).
Gal80-Gal80 interaction on adjacent Gal4p binding sites is required for complete GAL gene repression.
  EMBO J, 20, 841-851.  
12779444 K.W.Kohn (2001).
Molecular interaction maps as information organizers and simulation guides.
  Chaos, 11, 84-97.  
11119650 N.Majeux, M.Scarsi, and A.Caflisch (2001).
Efficient electrostatic solvation model for protein-fragment docking.
  Proteins, 42, 256-268.  
11139314 O.Tominaga, K.Unsal, G.Zalcman, and T.Soussi (2001).
Detection of p73 antibodies in patients with various types of cancer: immunological characterization.
  Br J Cancer, 84, 57-63.  
11316794 P.Hidalgo, A.Z.Ansari, P.Schmidt, B.Hare, N.Simkovich, S.Farrell, E.J.Shin, M.Ptashne, and G.Wagner (2001).
Recruitment of the transcriptional machinery through GAL11P: structure and interactions of the GAL4 dimerization domain.
  Genes Dev, 15, 1007-1020.
PDB code: 1hbw
11599019 P.S.Galatin, and D.J.Abraham (2001).
QSAR: hydropathic analysis of inhibitors of the p53-mdm2 interaction.
  Proteins, 45, 169-175.  
11148027 R.Stoll, C.Renner, S.Hansen, S.Palme, C.Klein, A.Belling, W.Zeslawski, M.Kamionka, T.Rehm, P.Mühlhahn, R.Schumacher, F.Hesse, B.Kaluza, W.Voelter, R.A.Engh, and T.A.Holak (2001).
Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.
  Biochemistry, 40, 336-344.  
11416126 S.Aratani, R.Fujii, T.Oishi, H.Fujita, T.Amano, T.Ohshima, M.Hagiwara, A.Fukamizu, and T.Nakajima (2001).
Dual roles of RNA helicase A in CREB-dependent transcription.
  Mol Cell Biol, 21, 4460-4469.  
11400116 T.Koga, S.Hashimoto, K.Sugio, I.Yoshino, K.Nakagawa, Y.Yonemitsu, K.Sugimachi, and K.Sueishi (2001).
Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.
  Int J Cancer, 95, 232-239.  
11581402 Z.Deng, C.J.Chen, D.Zerby, H.J.Delecluse, and P.M.Lieberman (2001).
Identification of acidic and aromatic residues in the Zta activation domain essential for Epstein-Barr virus reactivation.
  J Virol, 75, 10334-10347.  
10885605 H.Bouzourene, P.Gervaz, J.P.Cerottini, J.Benhattar, P.Chaubert, E.Saraga, S.Pampallona, F.T.Bosman, and J.C.Givel (2000).
p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
  Eur J Cancer, 36, 1008-1015.  
10679470 K.S.Gajiwala, and S.K.Burley (2000).
Winged helix proteins.
  Curr Opin Struct Biol, 10, 110-116.  
12760066 L.B.Schultz, N.H.Chehab, A.Malikzay, R.A.DiTullio, E.S.Stavridi, and T.D.Halazonetis (2000).
The DNA damage checkpoint and human cancer.
  Cold Spring Harb Symp Quant Biol, 65, 489-498.  
  10673500 N.H.Chehab, A.Malikzay, M.Appel, and T.D.Halazonetis (2000).
Chk2/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53.
  Genes Dev, 14, 278-288.  
10860994 S.Jin, S.Martinek, W.S.Joo, J.R.Wortman, N.Mirkovic, A.Sali, M.D.Yandell, N.P.Pavletich, M.W.Young, and A.J.Levine (2000).
Identification and characterization of a p53 homologue in Drosophila melanogaster.
  Proc Natl Acad Sci U S A, 97, 7301-7306.  
11498389 U.M.Moll, and A.Zaika (2000).
Disrupting the p53-mdm2 interaction as a potential therapeutic modality.
  Drug Resist Updat, 3, 217-221.  
  10452616 C.D.Thanos, and J.U.Bowie (1999).
p53 Family members p63 and p73 are SAM domain-containing proteins.
  Protein Sci, 8, 1708-1710.  
10561590 C.Götz, S.Kartarius, P.Scholtes, W.Nastainczyk, and M.Montenarh (1999).
Identification of a CK2 phosphorylation site in mdm2.
  Eur J Biochem, 266, 493-501.  
10025401 E.E.Zheleznova, P.N.Markham, A.A.Neyfakh, and R.G.Brennan (1999).
Structural basis of multidrug recognition by BmrR, a transcription activator of a multidrug transporter.
  Cell, 96, 353-362.
PDB codes: 1bow 2bow
  9882325 G.G.Prikhod'ko, Y.Wang, E.Freulich, C.Prives, and L.K.Miller (1999).
Baculovirus p33 binds human p53 and enhances p53-mediated apoptosis.
  J Virol, 73, 1227-1234.  
10075936 J.M.Stommel, N.D.Marchenko, G.S.Jimenez, U.M.Moll, T.J.Hope, and G.M.Wahl (1999).
A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking.
  EMBO J, 18, 1660-1672.  
10394359 J.Marcotrigiano, A.C.Gingras, N.Sonenberg, and S.K.Burley (1999).
Cap-dependent translation initiation in eukaryotes is regulated by a molecular mimic of eIF4G.
  Mol Cell, 3, 707-716.
PDB codes: 1ej4 1ejh
10469174 J.Ozaki, K.I.Takemaru, T.Ikegami, M.Mishima, H.Ueda, S.Hirose, Y.Kabe, H.Handa, and M.Shirakawa (1999).
Identification of the core domain and the secondary structure of the transcriptional coactivator MBF1.
  Genes Cells, 4, 415-424.  
  10436023 K.W.Kohn (1999).
Molecular interaction map of the mammalian cell cycle control and DNA repair systems.
  Mol Biol Cell, 10, 2703-2734.  
10047576 L.Chen (1999).
Combinatorial gene regulation by eukaryotic transcription factors.
  Curr Opin Struct Biol, 9, 48-55.  
10562558 M.Gostissa, A.Hengstermann, V.Fogal, P.Sandy, S.E.Schwarz, M.Scheffner, and G.Del Sal (1999).
Activation of p53 by conjugation to the ubiquitin-like protein SUMO-1.
  EMBO J, 18, 6462-6471.  
10584701 M.Hisaoka, Y.Morimitsu, H.Hashimoto, T.Ishida, H.Mukai, H.Satoh, T.Motoi, and R.Machinami (1999).
Retroperitoneal liposarcoma with combined well-differentiated and myxoid malignant fibrous histiocytoma-like myxoid areas.
  Am J Surg Pathol, 23, 1480-1492.  
10562557 M.S.Rodriguez, J.M.Desterro, S.Lain, C.A.Midgley, D.P.Lane, and R.T.Hay (1999).
SUMO-1 modification activates the transcriptional response of p53.
  EMBO J, 18, 6455-6461.  
10651272 M.Scarsi, N.Majeux, and A.Caflisch (1999).
Hydrophobicity at the surface of proteins.
  Proteins, 37, 565-575.  
10611293 M.Uesugi, and G.L.Verdine (1999).
The alpha-helical FXXPhiPhi motif in p53: TAF interaction and discrimination by MDM2.
  Proc Natl Acad Sci U S A, 96, 14801-14806.  
10570149 N.H.Chehab, A.Malikzay, E.S.Stavridi, and T.D.Halazonetis (1999).
Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage.
  Proc Natl Acad Sci U S A, 96, 13777-13782.  
10507764 N.Veldhoen, J.Watterson, M.Brash, and J.Milner (1999).
Identification of tumour-associated and germ line p53 mutations in canine mammary cancer.
  Br J Cancer, 81, 409-415.  
10415337 R.Zhou, H.Wen, and S.Z.Ao (1999).
Identification of a novel gene encoding a p53-associated protein.
  Gene, 235, 93.  
10419603 T.J.McDonnell, R.Montes de Oca Luna, S.Cho, L.L.Amelse, A.Chavez-Reyes, and G.Lozano (1999).
Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice.
  J Pathol, 188, 322-328.  
  10203572 T.Juven-Gershon, and M.Oren (1999).
Mdm2: the ups and downs.
  Mol Med, 5, 71-83.  
10202144 T.Unger, T.Juven-Gershon, E.Moallem, M.Berger, R.Vogt Sionov, G.Lozano, M.Oren, and Y.Haupt (1999).
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2.
  EMBO J, 18, 1805-1814.  
9811836 A.Z.Ansari, R.J.Reece, and M.Ptashne (1998).
A transcriptional activating region with two contrasting modes of protein interaction.
  Proc Natl Acad Sci U S A, 95, 13543-13548.  
  9808622 B.D.Darimont, R.L.Wagner, J.W.Apriletti, M.R.Stallcup, P.J.Kushner, J.D.Baxter, R.J.Fletterick, and K.R.Yamamoto (1998).
Structure and specificity of nuclear receptor-coactivator interactions.
  Genes Dev, 12, 3343-3356.
PDB code: 1bsx
  9566884 C.Schuster, A.Krol, and P.Carbon (1998).
Two distinct domains in Staf to selectively activate small nuclear RNA-type and mRNA promoters.
  Mol Cell Biol, 18, 2650-2658.  
9741622 D.Liu, R.Ishima, K.I.Tong, S.Bagby, T.Kokubo, D.R.Muhandiram, L.E.Kay, Y.Nakatani, and M.Ikura (1998).
Solution structure of a TBP-TAF(II)230 complex: protein mimicry of the minor groove surface of the TATA box unwound by TBP.
  Cell, 94, 573-583.
PDB code: 1tba
9606977 G.Lozano, and R.Montes de Oca Luna (1998).
MDM2 function.
  Biochim Biophys Acta, 1377, M55-M59.  
9671804 J.Momand, D.Jung, S.Wilczynski, and J.Niland (1998).
The MDM2 gene amplification database.
  Nucleic Acids Res, 26, 3453-3459.  
9529248 J.Pomerantz, N.Schreiber-Agus, N.J.Liégeois, A.Silverman, L.Alland, L.Chin, J.Potes, K.Chen, I.Orlow, H.W.Lee, C.Cordon-Cardo, and R.A.DePinho (1998).
The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.
  Cell, 92, 713-723.  
9430646 J.Roth, M.Dobbelstein, D.A.Freedman, T.Shenk, and A.J.Levine (1998).
Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.
  EMBO J, 17, 554-564.  
9736617 L.T.Jensen, and D.R.Winge (1998).
Identification of a copper-induced intramolecular interaction in the transcription factor Mac1 from Saccharomyces cerevisiae.
  EMBO J, 17, 5400-5408.  
9504235 M.Akashi, and H.P.Koeffler (1998).
Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility.
  Clin Obstet Gynecol, 41, 172-199.  
  9525640 M.E.Martin, and A.J.Berk (1998).
Adenovirus E1B 55K represses p53 activation in vitro.
  J Virol, 72, 3146-3154.  
  9742086 M.H.Kubbutat, R.L.Ludwig, M.Ashcroft, and K.H.Vousden (1998).
Regulation of Mdm2-directed degradation by the C terminus of p53.
  Mol Cell Biol, 18, 5690-5698.  
10211113 M.O'Neill, S.J.Campbell, V.Save, A.M.Thompson, and P.A.Hall (1998).
An immunochemical analysis of mdm2 expression in human breast cancer and the identification of a growth-regulated cross-reacting species p170.
  J Pathol, 186, 254-261.  
  9418889 O.Rowland, and J.Segall (1998).
A hydrophobic segment within the 81-amino-acid domain of TFIIIA from Saccharomyces cerevisiae is essential for its transcription factor activity.
  Mol Cell Biol, 18, 420-432.  
  9742099 P.C.McAndrew, J.Svaren, S.R.Martin, W.Hörz, and C.R.Goding (1998).
Requirements for chromatin modulation and transcription activation by the Pho4 acidic activation domain.
  Mol Cell Biol, 18, 5818-5827.  
  9708447 S.E.Bray, C.Schorl, and P.A.Hall (1998).
The challenge of p53: linking biochemistry, biology, and patient management.
  Stem Cells, 16, 248-260.  
9519295 S.Tan, and T.J.Richmond (1998).
Eukaryotic transcription factors.
  Curr Opin Struct Biol, 8, 41-48.  
  9632782 T.Juven-Gershon, O.Shifman, T.Unger, A.Elkeles, Y.Haupt, and M.Oren (1998).
The Mdm2 oncoprotein interacts with the cell fate regulator Numb.
  Mol Cell Biol, 18, 3974-3982.  
9646028 Y.Li, M.Bhuiyan, V.K.Vaitkevicius, and F.H.Sarkar (1998).
Molecular analysis of the p53 gene in pancreatic adenocarcinoma.
  Diagn Mol Pathol, 7, 4-9.  
9626190 Y.Tu, S.T.Hou, Z.Huang, G.S.Robertson, and J.P.MacManus (1998).
Increased Mdm2 expression in rat brain after transient middle cerebral artery occlusion.
  J Cereb Blood Flow Metab, 18, 658-669.  
9382809 A.Böttger, V.Böttger, A.Sparks, W.L.Liu, S.F.Howard, and D.P.Lane (1997).
Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo.
  Curr Biol, 7, 860-869.  
9039259 A.J.Levine (1997).
p53, the cellular gatekeeper for growth and division.
  Cell, 88, 323-331.  
9312058 A.L.Okorokov, F.Ponchel, and J.Milner (1997).
Induced N- and C-terminal cleavage of p53: a core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N-terminus of full-length p53, whereas ssDNA induces C-terminal cleavage of p53.
  EMBO J, 16, 6008-6017.  
  9131587 D.A.Freedman, C.B.Epstein, J.C.Roth, and A.J.Levine (1997).
A genetic approach to mapping the p53 binding site in the MDM2 protein.
  Mol Med, 3, 248-259.  
9357310 D.P.Lane, and P.A.Hall (1997).
MDM2--arbiter of p53's destruction.
  Trends Biochem Sci, 22, 372-374.  
9413984 I.Radhakrishnan, G.C.Pérez-Alvarado, D.Parker, H.J.Dyson, M.R.Montminy, and P.E.Wright (1997).
Solution structure of the KIX domain of CBP bound to the transactivation domain of CREB: a model for activator:coactivator interactions.
  Cell, 91, 741-752.
PDB code: 1kdx
9368757 J.B.Wallingford, D.W.Seufert, V.C.Virta, and P.D.Vize (1997).
p53 activity is essential for normal development in Xenopus.
  Curr Biol, 7, 747-757.  
9667874 J.P.Wery, and R.W.Schevitz (1997).
New trends in macromolecular X-ray crystallography.
  Curr Opin Chem Biol, 1, 365-369.  
  9372954 L.J.Ko, S.Y.Shieh, X.Chen, L.Jayaraman, K.Tamai, Y.Taya, C.Prives, and Z.Q.Pan (1997).
p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner.
  Mol Cell Biol, 17, 7220-7229.  
9384532 M.D.Shair (1997).
A closer view of an oncoprotein-tumor suppressor interaction.
  Chem Biol, 4, 791-794.  
9155025 M.S.Finnin, M.P.Cicero, C.Davies, S.J.Porter, S.W.White, and K.N.Kreuzer (1997).
The activation domain of the MotA transcription factor from bacteriophage T4.
  EMBO J, 16, 1992-2003.
PDB code: 1bja
11091612 M.Toi, S.Saji, A.Suzuki, Y.Yamamoto, and T.Tominaga (1997).
MDM2 in Breast Cancer.
  Breast Cancer, 4, 264-268.  
9358152 P.A.Defossez, J.L.Baert, M.Monnot, and Launoit (1997).
The ETS family member ERM contains an alpha-helical acidic activation domain that contacts TAFII60.
  Nucleic Acids Res, 25, 4455-4463.  
9458382 P.Würl, A.Meye, D.Berger, M.Bache, C.Lautenschläger, H.Schmidt, H.Kalthoff, F.W.Rath, and H.Taubert (1997).
Prognostic relevance of C-terminal Mdm2 detection is enhanced by p53 positivity in soft tissue sarcomas.
  Diagn Mol Pathol, 6, 249-254.  
9363941 S.Y.Shieh, M.Ikeda, Y.Taya, and C.Prives (1997).
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2.
  Cell, 91, 325-334.  
  9401021 V.Svetlov, and T.G.Cooper (1997).
The minimal transactivation region of Saccharomyces cerevisiae Gln3p is localized to 13 amino acids.
  J Bacteriol, 179, 7644-7652.  
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB code is shown on the right.